What does the new FDA guidance mean for clinical trials in early Alzheimer’s disease?
The latest FDA draft guidance for clinical trials in early Alzheimer’s disease presents many new opportunities and challenges for drug development.
WEBINAR: Finding the right patients for clinical trials in early Alzheimer's disease
Dr Kenton Zavitz, Director of Clinical Affairs at Cambridge Cognition, and Dr Robert Smith, Consultant Neuropsychologist, hosted a webinar to discuss clinical trials for early Alzheimer’s disease.
Join them to hear more about overcoming the barriers to expedite the drug development process.
Tuesday 22nd May 2018, 11 a.m. EDT
web-based testing, wearables, voice recognition, voice, virtual clinical trials, technology, swm, subjective measures, stress, social cognition, smartphones, schizophrenia, safety, rvp, rti, research funding, research, remote testing, recruitment, psychosis, prodromal, pro-cognitive, prm, press release, presenteeism, precision psychiatry, poster, personalised medicine, patient-centric, patient recruitment, parkinson's disease, pal, ots, occupational health, objective measures, normative data, neuroscience, near-patient testing, multiple sclerosis, mts, ms, mental wellbeing, mental health at work, mental health, mdd, mci, major depression, machine learning, longitudinal, life at cambridge cognition, international women's day, hot cognition, healthcare, grant, funding, fatigue, ert, epidemiology, ecoa, ebt, early career researchers, early alzheimer's disease, dms, digital tools, digital health, depression, dementia, covid-19, cognitive wellbeing, cognitive testing, cognitive science, cognitive safety, cognitive impairment, cognitive function, cognitive dysfunction, cognitive deficits, cognitive biomarkers, cognitive assessment, cognition kit, cognition, cns summit, clinical trials, clinical trial, cias, chronic illness, chronic health conditions, cgt, cantab testimonial, cantab research grant, cantab, cambridge cognition careers, cambridge cognition, brain health, bipolar disorder, biomarkers, automatic speech recognition, attention, alzheimer's disease, academic, absenteeism,